Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial

被引：3
|
作者：
Correll, Christoph U. [1 ,2 ,3 ]
Miller, Andrew C. [4 ]
Sawchak, Sharon [4 ]
Kaul, Inder [4 ]
Paul, Steven M. [4 ]
Brannan, Stephen K. [4 ]
机构：
[1] Zucker Hillside Hosp, Glen Oaks, NY USA
[2] Hofstra Northwell, Donald & Barbara Zucker Sch Med, Hempstead, NY USA
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Karuna Therapeut, Boston, MA USA
来源：
CNS SPECTRUMS | 2023年 / 28卷 / 02期
关键词：
D O I：
10.1017/S1092852923001360
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [1] Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
    Christoph U. Correll
    Angel S. Angelov
    Andrew C. Miller
    Peter J. Weiden
    Stephen K. Brannan
    Schizophrenia, 8
  • [2] Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
    Correll, Christoph U.
    Angelov, Angel S.
    Miller, Andrew C.
    Weiden, Peter J.
    Brannan, Stephen K.
    SCHIZOPHRENIA, 2022, 8 (01)
  • [3] Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
    Kaul, Inder
    Sawchak, Sharon
    Correll, Christoph U.
    Kakar, Rishi
    Breier, Alan
    Zhu, Haiyuan
    Miller, Andrew C.
    Paul, Steven M.
    Brannan, Stephen K.
    LANCET, 2024, 403 (10422): : 160 - 170
  • [4] HEPATIC SAFETY OF KARXT (XANOMELINE AND TROSPIUM CHLORIDE): POOLED RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
    Claxton, Amy
    Marcus, Ronald
    Ruan, Shiling
    Kaul, Inder
    Sauder, Colin
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 533 - 534
  • [5] SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
    Kramer, Kenneth
    Brannan, Stephen K.
    Sauder, Colin
    Kaul, Inder
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i162 - i162
  • [6] Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial (vol 403, pg 160, 2024)
    Jones, Caitlin M. P.
    Day, Richard O.
    Koes, Bart W.
    Latimer, Jane
    Maher, Chris G.
    McLachlan, Andrew J.
    Billot, Laurent
    Shan, Sana
    Lin, Chung-Wei Christine
    LANCET, 2024, 403 (10442): : 2380 - 2380
  • [7] CARDIOVASCULAR SAFETY AND TOLERABILITY OF KARXT (XANOMELINE AND TROSPIUM CHLORIDE) IN PEOPLE WITH SCHIZOPHRENIA: POOLED RESULTS FROM THE 5-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
    Sauder, Colin
    Vandell, Alexander G.
    Ramsey, Ian
    Claxton, Amy
    Ruan, Shilling
    Marcus, Ronald
    Kaul, Inder
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 528 - 529
  • [8] KarXT (Xanomeline-Trospium) Demonstrates Broad Efficacy in People With Schizophrenia Across a Wide Range of Demographic Subgroups: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled Emergent Trials
    Kaul, Inder
    Correll, Christoph
    Sawchak, Sharon
    Miller, Andrew
    Paul, Steven
    Brannan, Stephen K.
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 349 - 350
  • [9] Karxt (Xanomeline-Trospium) for the Treatment of Agitation in Schizophrenia: PANSS-EC Results From Three Randomized, Double-Blind, Placebo-Controlled Trials
    Yeung, Paul
    Breier, Alan
    Brannan, Stephen K.
    Zhu, Haiyuan
    Kaul, Inder
    Marcus, Ronald N.
    Paul, Steven M.
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 350 - 350
  • [10] Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
    Sauder, Colin
    Allen, Luke A.
    Baker, Elizabeth
    Miller, Andrew C.
    Paul, Steven M.
    Brannan, Stephen K.
    TRANSLATIONAL PSYCHIATRY, 2022, 12 (01)
12345